Feasibility of Carbon-Dye Marking of Axillary Lymph Nodes Before Neoadjuvant Chemotherapy in Patients With Breast Cancer
Breast Cancer
About this trial
This is an interventional diagnostic trial for Breast Cancer focused on measuring breast cancer, Lymph node metastasis, Targeted axillary dissection, Nodal marking
Eligibility Criteria
Inclusion Criteria: Patients with locally advanced breast cancer known to have metastases to the axillary lymph nodes at baseline and referred for neoadjuvant chemotherapy will be included in the study. Exclusion Criteria: diagnosis by excisional biopsy previous axillary surgery failure to complete neoadjuvant therapy progression during therapy.
Sites / Locations
- Gaziosmanpasa Training and Research HospitalRecruiting
Arms of the Study
Arm 1
Other
Carbon Black Tattoo arm
In patients with breast cancer diagnosed with positive axillary lymph node involvement by fine needle aspiration cytology, 0.1-0.5 ml Carbon Black Tattoo dye will be applied simultaneously to the lymph node capsule and surrounding tissue, while clips are placed on the axilla before starting neoadjuvant chemotherapy. After the neoadjuvant treatment is completed, the patient who is taken into surgery will be injected with periareolar blue dye as in the standard practice, and blue stained node, clipped node and carbon stained node will be searched as sentinal lymph node. The removed lymph nodes will be evaluated histopathologically in terms of metastasis with a frozen study during the operation, and if metastasis is detected, axillary lymph node dissection will be performed